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Although the architecture of tripartite multiple drug resistance (MDR) efﬂux pumps of Gram-nega-
tive bacteria has been well characterized, the means by which the components recognize each other
and assemble into a functional pump remains obscure. In this study we present evidence that the C-
terminal domain of the Pseudomonas aeruginosa OprM and the a-helical hairpin domain of Vibrio
cholerae VceA play an important role in the recognition/speciﬁcity/recruitment step in the assembly
of a functional, VceAB-OprM chimeric efﬂux pump. To our knowledge, this is the ﬁrst evidence
directly linking the C-terminal domain of an outer membrane efﬂux protein to its recruitment dur-
ing the assembly of a tripartite efﬂux pump.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Active efﬂux is now recognized as one of the major intrinsic
mechanisms of multiple drug resistance for bacteria. Unlike most
transporters, which are speciﬁc for a single substrate, a single mul-
tidrug resistance (MDR) efﬂux pump can effectively remove multi-
ple substrates, including bile acids, detergents, metabolic toxins,
and a broad spectrum of antibiotics [1]. Furthermore, an expansion
in their substrate proﬁle as well as an increase in their expression
can be brought about by mutation [2–4]. Hence, MDR efﬂux pumps
can present a serious impediment to antibiotic therapy. Decipher-
ing their mechanisms of action and assembly will be paramount to
the rational design and development of new drugs that can either
inactivate or circumvent their action.
In Gram-negative bacteria, these MDR pumps are often tripar-
tite in nature, comprised of three genetically distinct proteins:
the cytoplasmic membrane transporter (CMT), which bridges the
cytoplasmic membrane and provides substrate speciﬁcity and the
energy for the transport of substrate [2]; the outer membrane
channel or efﬂux protein (OEP) [5], which forms a channel across
the outer membrane; and a periplasmic accessory or membrane
fusion protein (MFP), which is often tethered to the cytoplasmic
membrane and is thought to consolidate the CMT and OEP to form
a continuous channel that bridges both membranes of the Gram-
negative cell envelope and the intervening periplasm, and enableschemical Societies. Published by E
icrobiology and Immunology
street Lubbock, TX 79430.
).the removal of substrates from the outer leaﬂet of the cytoplasmic
membrane to the outside of the outer membrane barrier [6].
Although crystal structures exist for all three components of
two well studied MDR efﬂux pumps (e.g. AcrAB-TolC and Mex-
AB-OprM) [7–12], the details by which these components recog-
nize each other and assemble into a functional efﬂux pump is
only beginning to be deciphered. One approach to examine the
interactions between the different components of functional
MDR efﬂux pumps has been to isolate gain-of-function (gof) mu-
tants that enable non-functional chimeric MDR efﬂux pumps to
function [3]. It is assumed that such mutations will identify key
locations in the interacting components and provide clues as to
mechanisms of speciﬁcity, recruitment and assembly. Using this
approach we [2] and others [13] have identiﬁed the periplasmic
tips in helices H3, H4 and H8 of VceC, the OEP of the V. cholera
VceAB-VceC MDR efﬂux pump and TolC, the OEP for the AcrAB-
TolC MDR efﬂux pump in Escherichia coli as important sites for
the functional assembly of the AcrAB-VceC and MexAB-TolC chi-
meric efﬂux pumps respectively. A similar test has implicated the
a-hairpin domain of MexA in the functional assembly of the Mex-
AB-OprN chimeric pump [14]. Others have also mapped such inter-
actions through genetic [3,4,15–18] as well as chemical [1,19–27]
studies and have been summarized in several recent reviews
[28–30].
In this study, we have found that originally cloned and se-
quenced OprM [31], which functions with MexAB, could not func-
tion with the VceAB translocase, whereas its wild-type
counterpart [32] could. The difference between these two func-
tional OprMs lies in their C-terminal sequence. The originallylsevier B.V. All rights reserved.
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placed by 14 non-homologous amino acids derived from its origi-
nal phagemid cloning vehicle [31]. We call this OprM derivative,
OprM22/14. In this study we have found that gain-of-function
mutations that enable OprM22/14 to functionally interact with
VceAB map to the tip of the VceA a-hairpin domain, including
VceAD155Y. We have also found that OprM22/14 could not be
cross-linked to VceA but could be cross-linked to the gain-of-
function VceAD155Y mutant, suggesting that the defect in the
VceAB-OprM22/14 chimeric efﬂux pump resides in the recruitment
of OprM22/14 for assembly.
2. Materials and methods
2.1. Bacterial strains, plasmids, and media
Bacterial strains and plasmids used in this study are listed in
Table 1. E. coli strains were routinely grown in Luria broth (LB)
[33] in a gyratory shaking water bath (New Brunswick) at 250
rpm at 37 C unless otherwise speciﬁed. Tetracycline, chloram-
phenicol, carbenicillin, and novobiocin were used at 12.5, 30,
100, and 20 lg/ml respectively.
2.2. Drug sensitivity determination
The minimum inhibition concentration (MIC) of the inhibitor
was determined as described by Vediyappan et al. [2] The MICs
are the average of three or more independent determinations
rounded to the nearest whole number.
2.3. Site-directed mutagenesis
Site-directed mutagenesis was conducted by using the Quick-
Change Mutagenesis Kit (Stratagene, Inc.) according to the user
manual. A plasmid carrying wild-type vceAB (pVC41 or pVC4)
was used as the mutagenesis template. The mutagenesis oligonu-Table 1
Bacterial strains and plasmids used in this study.
Strain Relevant characteristics Reference
E. coli
LBB1274 CC118, phoA20 thi-1 rspE rpoB argE recA1
(SpectR)
Lab
collection
LBB1600 tolC derivative of LBB1274 (SpectR) Lab
collection
Plasmid
pVC4 pBR322::vceAB (CbR) [35]
pVC41 pACYC184::vceAB (CAPR) [35]
pVC91 pBR322::vceC (CbR) [35]
pVC4AD155Y-6H 6-His tag on C-terminus of vceAD155Y (CbR) This
study
pVC4A-6H 6-His tag on C-terminus of vceA (CbR) This
study
pRSP19 pRK415::mexAB (TetR) [46]
pRSP08 pRK415::oprM22/14 (gi/404773/) (TetR) [46]
pLACOWT pLAC11::oprM (gi/15595624/) (with
upstream 800 bps) (CbR)
This
study
pVC41D155Y pACYC184::vceAD155YB (CAPR) This
study
pVC41S167A pACYC184::vceAS167AB (CAPR) This
study
pVC41Q182K pACYC184::vceAQ182KB (CAPR) This
study
pVC41M194I pACYC184::vceAM194IB (CAPR) This
study
pVC41M194I+D155A pACYC184::vceAM194I+D155AB (CAPR) This
study
Spect (Spectinomycin), Cb (Carbenicillin), Tet (Tetracycline), and CAP
(Chloramphenicaol).cleotides (Table 2) were obtained from Integrated DNA Technolo-
gies (Coralville, Iowa).
2.4. In vivo cross-linkage and membrane protein puriﬁcation
To stabilize protein–protein interactions, proteins were cross-
linked in vivo by dithiobis (succinimidyl propionate) (DSP), as de-
scribed by Thanabalu et al. [20]. LBB1600 (tolC derivative) carrying
either pVC4A-6H (C-terminal 6His-tag) or pVC4AD155Y-6H (C-ter-
minal 6His-tag) and pRSP08 were grown to a density of approxi-
mately 2  108 cells/ml and treated with DSP. Total membrane
preparations were obtained using a modiﬁcation of the differential
solubilization method of Schnaitman [34]. Cells were harvested by
centrifugation, and the pellets washed and resuspended in cold
0.05 M HEPES, pH 7.4, containing 2 mM phenylmethylsulfonyl
ﬂuoride (PMSF), and disrupted by passage through a French pres-
sure cell (type #43398A; Aminco, Silver Spring, MD.) at 1000 kg/
cm2. The cells were centrifuged at 5000g to remove unbroken
cells, and the supernatant was centrifuged at 200 000g for
45 min at 5 C to harvest total membranes (cytoplasmic and outer).
Column puriﬁcation of 6His-tagged proteins (and associated
proteins), were as described in the Novagen (EMD chemicals Inc.)
manual on NI-NTA His-Bind resins. The procedures were modiﬁed
as follows: the membrane pellet was resuspended in binding buf-
fer (8 M urea, 0.1 M sodium phosphate, 0.01 M Tris–HCl, pH 8.0)
(Novagen Inc). The protein samples were then mixed with 50%
His-Select Nickel Afﬁnity Gel (Sigma–Aldrich) which had been
washed with double-distilled water and binding buffer. The mix-
ture was mixed gently by rotating the loaded column for 90 min
at room temperature. The initial ﬂow-through was collected (con-
trol) and saved for sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) analysis. The column was then
washed with washing buffer (8 M urea, 0.1 M sodium phosphate,
0.01 M Tris–HCl, pH 6.5) six times, and the last washate saved
for SDS–PAGE analysis. The 6His-tagged proteins (and any cross-
linked proteins) were then eluted from the column with elution
buffer (8 M urea, 0.1 M sodium phosphate, 0.01 Tris–HCl, pH 4.5)
and analyzed by Western blot analysis.
2.5. Western blot analysis
The procedures of western blot analysis were as described by
Vediyappan et al. [2]. Proteins were resolved by 10% SDS–PAGE
and transferred to a polyvinylidenediﬂuoride (PVDF) membrane
(Bio-Rad, CA). Rabbit anti-VceA, rabbit anti-6His, and mouse anti-
OprM antibodies were used as primary antibodies at a dilution ofTable 2
Mutagenesis primers.
Name DNA sequence
vceA-6His-F 50-CAAAGTTTCAGAGCAAGGCCATCACCATCATCACCAThT
AAGGTGAATCCATGAGTC-30
vceA-6His-R 50-GACTCATGGATTCACCTTAATGGTGATGATGGTGATGGC
CTTGCTCTGAAACTTTG-30
vceAD155Y-F 50-CGAGCAAAAATCTATcTTATCTCGTCGGGAAGAC-30
vceAD155Y-R 50-GTCTTCCCGACGAGATAAATAGATTTTTGCTCG-30
vceAD155A-F 50-CGAGCAAAAATCGCTdTTATCTCGTCGGGAAGAC-30
vceAD155A-R 50-GTCTTCCCGACGAGATAAAGCGATTTTTGCTCG-30
vceAS167A-F 50-CTTAGTGCGTTCCGGCGCCeGTTTCTGGTGAAGA-30
vceAS167A-R 50-TCTTCACCAGAAACGGCGCCGGAACGCACTAAG-30
vceAQ182K-F 50-CAAAACCGGGTTTTGCGAAGfGCACAAGCAAACCT-30
vceAQ182K-R 50-AGGTTTGCTTGTGCCTTCGCAAAACCCGGTTTTG-30
vceAM194I-F 50-ACGCGGCAAAAGCGGCTATAgGCGCAAGCACAGGCAACTA-30
vceAM194I-R 50-TAGTTGCCTGTGCTTGCGCTATAGCCGCTTTTGCCGCGT-30
F and R represent forward and reverse primers respectively.
c d e f gOriginal codons are GAT, GAT, TCC, CAG and ATG respectively.
hCoding sequence for 6 histidines.
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(eBioscience) and anti-mouse IgG secondary antibody (Immuno-
Pure). Blots were developed employing SuperSignal West Pico
Chemiluminescent substrates (Pierce) and X-ray ﬁlms (Marsh Bio
Products, Inc., NY).
3. Results
3.1. The C-terminal sequence of OprM plays a role in the functioning of
the VceAB pump
E. coli tolC derivatives are hypersensitive to a variety of inhibi-
tory agents, including substrates for the VceAB pump [Carbonyl
cyanide m-Chlorophenylhydrazone (CCCP) and Deoxycholate
(DOC)] and thus provide a convenient system for analyzing the
functionality of the VceAB pump [35]. Sensitivity to Novobiocin
(NOV), which is not a substrate for the VceAB pump, was used as
a negative control. As a positive control, we included a plasmid that
encoded for the functional VceAB-VceC pump as well as plasmid
that encoded for the MexAB tanslocase. From the results presented
in Table 3 it can be seen that while both OprM and its derivative
OprM22/14 can function with the MexAB translocase, only wild-
type OprM can replace VceC in the functioning of the VceAB pump.
OprM22/14 cannot. This result suggests that the C-terminus of OprM
plays an important role in the functioning of the chimeric VceAB-
OprM efﬂux pump.
3.2. Isolation of gain-of-function (gof) mutants for the VceAB-OprM22/
14 efﬂux pump
In an attempt to further characterize the defect in the OprM
derivative, OprM22/14, that does not allow it to functionally interact
with the VceAB translocase, we have isolated gain-of-function
(suppressor) mutants, which enable VceAB-OprM22/14 to function
in E. coli.
TolC mutants (LBB1600) are hypersensitive to DOC and cannot
grow on LB agar plates containing 0.05% DOC (DOC plate) [36].
However, LBB1600 carrying a functional VceAB-VceC or VceAB-Table 3
Sensitivity of E. coli carrying vceAB/vceAgofB-oprM22/14/oprM/vceC to inhibitors.
Strains Genotype
LBB1274
LBB1600
LBB1600/pVC41 vceAB
LBB1600/pRSP19 mexAB
LBB1600/pRSP08 oprM22/14
LBB1600/pLACOWT oprM
LBB1600/pVC91 vceC
LBB1600/pVC41/pVC91 vceC vceAB
LBB1600/pVC41/pRSP08 oprM22/14 vceAB
LBB1600/pVC41/pLACOWT oprM vceAB
LBB1600/pRSP19/pRSP08 oprM22/14 mexAB
LBB1600/pRSP19/pLACOWT mexAB oprM
LBB1600/pRSP08/pVC41 oprM22/14 vceAB
LBB1600/pRSP08/pVC41D155Y oprM22/14 vceAD155YB
LBB1600/pRSP08/pVC41S167A oprM22/14 vceAS167AB
LBB1600/pRSP08/pVC41Q182K oprM22/14 vceAQ182KB
LBB1600/pRSP08/pVC41M194I oprM22/14 vceAM194IB
LBB1600/pRSP08/pVC41M194I+D155A oprM22/14 vceAM194I+D155AB
LBB1600/pVC91/pVC41 vceC vceAB
LBB1600/pVC91/pVC41D155Y vceC vceAD155YB
LBB1600/pLACOWT/pVC41 oprM vceAB
LBB1600/pLACOWT/pVC41D155Y oprM vceAD155YB
a Cyanide Carbonyl m-Chlorophenylhydrazon (CCCP).
b Novobiocin (NOV).
c Deoxycholate (DOC).OprM pump can. To isolate suppressor mutations, we grew multi-
ple cultures of LBB1600 harboring pVC41 (vceAB) and pRSP08
(oprM22/14) overnight, concentrated them by centrifugation and
spread approximately 109 cells from each culture on DOC plates.
Single colonies were picked from each DOC plate and checked for
DOC resistance. Plasmids were isolated from the gain-of-function
(gof) mutants and transformed into LBB1600 (tolC) cells. Those
transformants that obtained pRSP08 from the gof mutant (tetracy-
cline resistant/chloramphenicol sensitive) were transformed with
a wild-type pVC41 and those transformants that obtained pVC41
(chloramphenicol resistant/tetracycline sensitive) from the gof
mutant were transformed with a wild-type pRSP08. These double
transformants were then tested for growth on DOC plates to deter-
mine if they carried the gof mutation. Interestingly, all of the gof
mutations mapped to the pVC41 plasmid and upon sequence anal-
ysis we found that they mapped to four different residues in VceA:
D155, S167, Q182 and M194, with the majority of those isolated
mapping to D155. All gof mutations were conﬁrmed by in vitro
site-directed mutagenesis. Their sensitivities to CCCP, NOV and
DOC, compared to the VceAB-VceC and VceAB-OprM pumps are gi-
ven in Table 3. It should be noted that the spontaneous gof VceA
mutant proteins do not alter their ability to functionally interact
with VceB and VceC in a VceAgofB-VceC efﬂux pump, as determined
by sensitivity to CCCP and DOC in a tolC mutant (LBB1600) (Table
3).
3.3. Location of VceA gof mutations
We have utilized the Protein Homology/analogY Recognition
Engine (PHYRE) [37] to analyze the location of the gof mutations
on the tertiary structure of VceA. Although the PHYRE program
could not predict the structure of the region 180–200 on VceA, it
is clear that all of the gof mutations are located at the tip of the
a-helical hairpin domain of VceA (Fig. 1). It has been well docu-
mented that the a-hairpin domain of MFPs physically interact with
their cognate OEPs [22] and hence these results suggest that the
defect in OprM22/14 may involve its inability to interact with VceA.
It should also be pointed out that the location of the VceA D155YSensitivity (MIC)
CCCPa (mg/L) NOVb (mg/L) DOCc (mg/L)
8 >80 2.50  103
0.5 1.25 0.15  103
0.5 1.25 0.15  103
0.5 1.25 0.15  103
0.5 1.25 0.15  103
0.5 1.25 0.15  103
0.5 1.25 0.15  103
16 1.25 2.50  103
0.5 1.25 0.15  103
8 1.25 1.25  103
2 40 0.63  103
4 40 1.25  103
0.5 1.25 0.15  103
16 1.25 1.25  103
16 1.25 1.25  103
16 1.25 1.25  103
16 1.25 2.50  103
16 1.25 1.25  103
16 1.25 2.50  103
>16 1.25 2.50  103
8 1.25 1.25  103
16 1.25 2.50  103
Fig. 1. Locations of gof mutations on predicted structure of VceA. Labeled amino
acids (D155, S167, Q182 and M194) on VceA indicate the location of gof mutations,
which allowed VceAB to functionally interact with OprM22/14 in E. coli. Q182 and
M194 were predicted by using the closest residues next to them. Molecular
graphics images were produced using the UCSF Chimera package [45] from the
Resource for Biocomputing, Visualization, and Informatics at the University of
California, San Francisco (supported by NIH P41 RR-01081).
Fig. 2. Cross-linking analyses of OprM22/14 and VceA. Western blot analysis of
membrane protein samples from an E.coli strain (LBB1600) harboring either
pRSP08, pRSP08/pVC4A-6H, or pRSP08/pVC4AD155Y-6H, before (panel A); or after
(panel B) passing the cross-linked membrane protein samples through the His-
Select™ Nichel Afﬁnity Gel. The same amount of protein was applied to each
column for puriﬁcation. OprM22/14 and VceA were identiﬁed by blotting with mouse
anti-OprM and rabbit anti-6His antibodies, respectively.
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tated to an arginine enables it to functionally interact with, OprN
[14], an OEP with which it normally does not functionally interact.
3.4. Cross-linkage analysis of VceA and VceAD155Y to OprM22/14
To determine if the difference between in the functioning of
VceA and VceA gof mutants with OprM22/14 (in the VceAB-
OprM22/14 chimeric pump) may be the result of their ability to
physically interface with OprM22/14 (i.e. recruitment/docking), we
tested if we could chemically cross-link VceA and gofmutant VceA-
D155Y with OprM22/14. To do this we constructed C-terminal 6His-
tagged VceA (pVC4A-6H) and VceAD155Y (pVC4AD155Y-6H) mutants
by in vitro site-directed mutagenesis. The C-terminal 6His-tag did
not affect the functioning of these VceA derivatives as determined
by CCCP and DOC sensitivities (data not shown). The results from
in vivo cross-linkage with dithiobis (succinimidyl propionate)
(DSP), followed by puriﬁcation on a His-Select™ Nickel Afﬁnity
Gel (Sigma, Inc) are shown in Fig. 2. It can be seen that while we
can cross-link OprM22/14 to the gof VceAD155Y-6H we cannot
cross-link OprM22/14 to VceA-6H. These results suggest that the de-
fect in the OprM22/14 C-terminal modiﬁcation may be due to its
inability to be recognized/recruited by the VceAB translocase and
that the C-terminal region of OprM plays a role in the recruit-
ment/assembly of a functional VceAB-OprM MDR efﬂux pump.
4. Discussion
In this study, we have found that wild-type OprM can form a
functional efﬂux pump with MexAB and VceAB tranlocases, how-
ever, the OprM derivative, OprM22/14, an OprM with an altered C-
terminal domain, can only form a functional pump with its cognatetranslocase, MexAB [31] (Table 3). The fact that OprM22/14 can form
a functional pump with MexAB but not with VceAB suggests that
the C-terminal domain of OprM may play a role in the speciﬁc-
ity/recruitment/assembly of the VceAB-OprM chimeric efﬂux
pump and mutational studies have suggested that residues in this
domain in TolC are functionally important [38–40].
Current models for the assembly of tripartite pumps have sug-
gested that the assembly process involves two or more steps: (1)
the recruitment and physical docking of the OEP with its cognate
translocase; and (2) the opening of the OEP channel [12,41–44].
Our results suggest that it is the ﬁrst step: recognition/recruitment
of the OEP by the translocase that is affected by the C-terminal
modiﬁcation of OprM22/14. Such an interpretation is bolstered by
the fact that we cannot physically cross-link OprM22/14 with VceA
(Fig. 2) and that all gof mutations that enable it to functionally
interface with VceAB, map to the a-hairpin domain of VceA
(Fig. 1), which has been implicated in the recruitment of OEPs by
their cognate translocases [22].
The means by which the gain-of-function mutations in VceA en-
able OprM22/14 to physically and functionally interact with VceAB
is not known. However, it has not gone without notice that a
Q116R mutation in MexA, which aligns with the gof mutant VceA-
D155Y, enables the MexAB translocase to functionally interact
with OprN, an OEP with which it normally cannot function [14].
It should also be pointed out that the C-terminal residues altered
in OprM22/14 make up part of this OEPs equatorial domain [12].
and hence the effect of this alteration on its assembly with the
VceAB translocase may be mediated through an alteration of its
equatorial domain per se. It has been shown that a mutation in
the equatorial domain of TolC (V198D) enabled it to functionally
interact with MexAB, a translocase with which it normally cannot
function [13]. Furthermore, it has been shown that the tip of the
AcrAa-hairpin interacts with the intermolecular groove formed be-
tween the inner and outer entrance coils of TolC, which lie just be-
low the equatorial domain and that this interaction could be
supported by a cluster of speciﬁc hydrophobic residues which lie
within in the equatorial domain [22]. Obviously further studies
are needed to decipher the mechanism(s) by which the C-termi-
nal/equatorial domain of OEPs affects the recruitment/assembly
of OEPs into tripartite efﬂux pumps. However, because of its acces-
sibility, the C-terminal domain of OEPs may provide a target for
MDR efﬂux inhibitors.
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